CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised/Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up. (2026). SKIN The Journal of Cutaneous Medicine, 10(2), s756. https://doi.org/10.25251/hex0h755